In the hunt for a megablockbuster, Celgene plans FDA filing in wake of PhIII win for ozanimod in MS
When Celgene bought out Receptos and its autoimmune drug ozanimod back in 2015 for $7.2 billion in cash, the big biotech bullishly forecast their drug would be worth $4 billion to $6 billion in peak sales. Today, the executive crew started to make good on that projection with a positive readout on the top-line data from their Phase III multiple sclerosis study.
The company says it’s on track to file for an approval of the S1P1 receptor antagonist this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.